Health Care/Hospital

BioWorld by Clarivate Examines Impact of Emerging Medicines on Obesity

Three-part, in-depth analysis of biopharma investments in obesity medications highlights potential impact onpatient population historically faced with limited options LONDON, Oct. 24, 2023 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a global leader in connecting people and ...

2023-10-24 15:00 1335

Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair

TAIZHOU, China, Oct. 24, 2023 /PRNewswire/ -- From October 19 to 22, the 14th China (Taizhou) International Pharmaceutical Fair, sponsored by the China Chamber of International Commerce and hosted by the Taizhou Municipal People's Government andJiangsu Branch of the China Council for the Promotio...

2023-10-24 13:39 1948

Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards

SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Juniper Biologics , a global science-led pharmaceutical company headquartered inSingapore, has been honored with the prestigious title of the "Most Innovative Oncology Pharmaceutical Company 2023" by the Global Health & ...

2023-10-24 12:00 1434

Cellomics announces Mr. Andy A. Liu as new Group CEO of the Company

Hong Kong, Oct. 24, 2023 /PRNewswire/ -- Cellomics, the leader in liquid biopsy technology for cancer screening and precision diagnosis, is pleased to announce the appointment of Mr.Andy A. Liu as the new Group CEO of the company. With over 25 years of healthcare experience, Mr. Liu brings a weal...

2023-10-24 12:00 2339

CCTV+: Jianchangbang Pharmacy: A Thousand Years of Tradition and Excellence

BEIJING, Oct. 24, 2023 /PRNewswire/ -- As a living legacy of Jiangxi's rich culture of traditional Chinese medicine (TCM), the respected brand, Jianchangbang Pharmacy, carries forward the splendor of Chinese medical wisdom. It is a renowned sect of theSouth China ancient TCM school and TCM prepar...

2023-10-24 11:51 1694

Based on recent data presented at 2023 ESMO, the innovative TROP2 ADC SKB264 (MK-2870) shows promising prospects for the treatment of patients with HR+/HER2- metastatic breast cancer who have undergone multiple prior lines of therapy , and its clinical development in other solid tumors is also advancing steadily

CHENGDU, China, Oct. 24, 2023 /PRNewswire/ -- Human trophoblastic cell surface antigen 2 (TROP2) exhibits high expression in numerous solid tumors, making it a prominent target in recent oncology studies. The progress in the development of Antibody-Drug Conjugates (ADCs) against  this target has ...

2023-10-24 10:19 2451

Council of ASEAN Chief Justices reflect milestones and achievements over the past 10 years, and chart strategic agenda

SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- The Council of ASEAN Chief Justices (CACJ) held its inaugural retreat on 20 October to reaffirm the ASEAN Judiciaries' strategic and cohesive approach towards deepening judicial cooperation and upholding the Rule of Law. It was hosted by the Malaysian Jud...

2023-10-24 10:07 1501

Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO

* KN026 combined with docetaxel has significant efficacy in the first-line treatment of HER2-positive recurrent or metastatic breast cancer, with mPFS of 26.9 months and 24-month OS rate of 84.2%. * KN026 combined with docetaxel has significant efficacy and good tolerability in the neoadjuvan...

2023-10-24 08:41 3187

Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO

* KN046 showed encouraging efficacy result especially in OS benefit (mOS: 20.2 months) in advanced NSCLC with EGFR sensitivity mutation who progressed after EGFR-TKI(s). * KN046 showed encouraging efficacy result especially in OS benefit (mOS: 13.3months) in advanced NSCLC with EGFR sensitivi...

2023-10-24 08:41 1536

LifeSpan Vision Ventures Invests in Matter Bio

NORWALK, Conn., Oct. 24, 2023 /PRNewswire/ -- LifeSpan Vision Ventures today announced an investment in Matter Bio, a longevity holding company focused on preserving genome integrity. Central to the company's philosophy is that as we age, our genome is constantly being damaged by exogenous and en...

2023-10-24 03:40 1862

LBB Specialties Announces Principal Partnership with Viscofan

NORWALK, Conn., Oct. 23, 2023 /PRNewswire/ -- LBB Specialties (LBBS), a leader inspecialty chemicals and ingredients distribution in North America, announces a new partnership with Viscofan DE, a global leader in collagen manufacturing. LBB Specialties will be Viscofan's preferred partner inthe U...

2023-10-23 23:00 1533

XINGIMAGING and MITRO BIOTECH CO., LTD. MERGE TO DELIVER FULL-SERVICE CRO OPERATIONS TO GLOBAL RESEARCH INITIATIVES

NEW HAVEN, Conn., Oct. 23, 2023 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd., two recognized lead companies offering quality and excellence in drug development and imaging solutions, have merged to create one company dedicated to providing a full spectrum of CRO & CDMO research s...

2023-10-23 22:38 1594

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all patients treated in the expansion cohort PRINCETON, N.J. and SUZHOU, China, Oct. 23, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Tr...

2023-10-23 21:48 3884

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. SKY-0515's Phase 1 study will include healthy volunteers before targetingHuntington's patients. Huntington's disease is a fatal neurological disease with no curative therapies. WALTHAM, Ma...

2023-10-23 20:00 1168

The team from Kelun-Biotech held a meeting with representatives from MSD in Madrid, Spain

CHENGDU, China, Oct. 23, 2023 /PRNewswire/ -- On October 20, 2023, the European Society for Medical Oncology (ESMO) Conference grandly commenced inMadrid, Spain . The ESMO Conference is the most esteemed and influential oncology conference inEurope, and this annual event garners the participation ...

2023-10-23 18:16 1859

Global Healthcare Accreditation Welcomes Karin Jay as President of Global Strategy and Announces Renée-Marie Stephano's Transition to CEO

New Leadership Aims to Reinforce GHA's Position as the Foremost Authority in Medical and Well-being Travel Accreditation PALM BEACH GARDENS, Fla., Oct. 23, 2023 /PRNewswire/ -- Global Healthcare Accreditation (GHA), the esteemed authority in accreditation and certification with a specialized foc...

2023-10-23 18:00 1311

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

SHENZHEN, China, Oct. 23, 2023 /PRNewswire/ -- Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascu...

2023-10-23 17:53 1922

Pepsodent launches oral hygiene awareness campaign in Malaysia

Targeting B40 communities, the initiative in partnership with MAHSA University's Faculty of Dentistry and MYDIN Prihatin will include distribution of 60,000 toothpaste kits worldwide KUALA LUMPUR, Malaysia, Oct. 23, 2023 /PRNewswire/ -- Pepsodent, a family-trusted, halal oral care brand tod...

2023-10-23 16:30 1927

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

* HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials inAustralia, targeting multiple solid tumors * The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe treatment-re...

2023-10-23 14:23 1605

Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at JSA2023

TOKYO, Oct. 23, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a biotech company specializing in the development of treatments for allergy, asthma, nephrology, dermatology, ophthalmology and other autoimmune diseases, oral presented the phase I data of ...

2023-10-23 12:27 1775
1 ... 90919293949596 ... 566